{"product_id":"valneva-business-model-canvas","title":"Valneva Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva Business Model Canvas: Downloadable, Editable Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic logic behind Valneva's business model: this focused Business Model Canvas outlines value propositions, key partners, and revenue drivers to show how the company develops, manufactures, and commercializes preventive vaccines.\u003c\/p\u003e\n\u003cp\u003eDesigned for investors, consultants, and entrepreneurs, the downloadable Canvas provides editable Word and Excel files with company-specific insights and practical strategic takeaways.\u003c\/p\u003e\n\u003cp\u003ePurchase the full version to access all nine building blocks, financial implications, and ready-to-use slides for benchmarking or investor presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaboration with Pfizer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva's core partnership with Pfizer advances VLA15-Pfizer funds late-stage trials and will co-commercialize; Pfizer's 2024 global sales infrastructure (\u0026gt;$58bn revenue in 2024) shortens time-to-market and distribution reach. By end‑2025 the tie-up anchors Valneva's growth outlook as VLA15 progresses toward potential regulatory filings and peak-year market projections above €500m.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution Agreements with GSK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva's distribution agreement with GSK lets it sell IXIARO and DUKORAL through GSK's established channels in key markets, avoiding local infrastructure costs; in 2024 these vaccines drove ~€95m of Valneva product revenue, with GSK partnership markets contributing an estimated 40% of that total.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFunding from CEPI and Institutional Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva secures non-dilutive funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and institutional partners-CEPI committed up to $11.5m to IXCHIQ chikungunya support in 2023 and has funded endemic-area trials, lowering Valneva's trial spend and commercial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva partners with multiple contract manufacturing organizations (CMOs) to keep production flexible and scale capacity for travel vaccines; in 2024 CMOs handled roughly 30-40% of finished-dose output, helping avoid bottlenecks during peak seasons like Q2-Q3 summer travel.\u003c\/p\u003e\n\u003cp\u003eOutsourcing technical steps lets Valneva focus internal spend on R\u0026amp;D and specialized manufacturing-R\u0026amp;D expense was €79m in 2024-while CMOs reduce capital intensity and speed time-to-market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCMOs supply ~30-40% of finished-dose capacity (2024)\u003c\/li\u003e\n\u003cli\u003eMitigates seasonal peaks Q2-Q3\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D focused internally: €79m (2024)\u003c\/li\u003e\n\u003cli\u003eReduces capex and shortens lead times\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Military Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva holds long-term procurement contracts with government and military health agencies, notably the US Department of Defense for Japanese Encephalitis vaccine, securing multi-year demand that supported €110m-€130m vaccine revenue range in 2024 estimates for legacy products.\u003c\/p\u003e\n\u003cp\u003eThese contracts require strict quality audits and cold-chain logistics-areas where Valneva's manufacturing in Scotland and Sweden meets DoD standards, reducing fulfillment risk and stabilizing cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDoD contract: multi-year supply for JEV\u003c\/li\u003e\n\u003cli\u003e2024 vaccine revenue: ~€110m-€130m estimate\u003c\/li\u003e\n\u003cli\u003eRequires GMP audits + cold-chain logistics\u003c\/li\u003e\n\u003cli\u003eManufacturing sites: Scotland, Sweden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva de‑risked by Pfizer, GSK, CEPI, CMOs \u0026amp; DoD-backed by €58bn+ network, multi‑year demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva's key partners (Pfizer, GSK, CEPI, CMOs, DoD) de‑risk commercialization, fund late‑stage trials, and secure multi‑year demand; Pfizer partnership leverages \u0026gt;€58bn 2024 sales network, CEPI gave $11.5m (2023), CMOs handled 30-40% finished doses (2024), and legacy vaccines drove ~€110-130m revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey 2023-24 figures\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eCo‑dev\/commercial\u003c\/td\u003e\n\u003ctd\u003ePfizer sales \u0026gt;€58bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGSK\u003c\/td\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eValneva vaccines €95m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEPI\u003c\/td\u003e\n\u003ctd\u003eNon‑dilutive funding\u003c\/td\u003e\n\u003ctd\u003e$11.5m commit (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003e30-40% finished doses (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoD\u003c\/td\u003e\n\u003ctd\u003eMulti‑year buyer\u003c\/td\u003e\n\u003ctd\u003eLegacy rev €110-130m (2024 est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Business Model Canvas for Valneva outlining its vaccine-focused value propositions, key partners, R\u0026amp;D and manufacturing capabilities, target customer segments, channels, revenue streams, and cost structure, with linked competitive advantages and risks to support investor and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Valneva's vaccine-focused business model with editable cells to quickly pinpoint value drivers, revenue streams, and R\u0026amp;D dependencies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development of Vaccine Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva's R\u0026amp;D centers on advancing vaccine candidates for high unmet infectious diseases via lab research, antigen selection, and delivery-platform optimization; R\u0026amp;D spend was €76.8M in 2024 and pipeline investments pivoted in 2025 toward lifecycle extension of Ixiaro and VLA15 plus preclinical push for two new candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management and Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva runs complex Phase 1-3 trials, spending ~€120-150M annually on R\u0026amp;D in 2024-25 to prove safety and efficacy across dozens of global sites; trials demand coordinated site management, strict ethics (ICH-GCP), and precise data capture to support filings. Successful outcomes are required for regulatory submissions and market entry, e.g., the Lyme vaccine pivotal data due 2025-26 will determine EU\/US approval timelines and revenue start.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized GMP Vaccine Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva runs GMP vaccine plants in Livingston (Scotland), Solna (Sweden) and Vienna (Austria), producing viral antigens and final vaccine formulations for global markets; in 2024 these sites supported company revenue of €122.8m and 1 commercial vaccine in late-stage supply. Maintaining them requires continuous QC (batch release testing for \u0026gt;100 parameters), equipment upkeep averaging €12-15m CAPEX\/year, and compliance with evolving EU and WHO safety and environmental rules.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva's regulatory affairs shepherd FDA and EMA filings-including Biologics License Applications (BLAs)-and post-approval compliance, securing market access and enabling label expansions; regulatory spend was ~€45m in 2024 to support COVID-19 and Ixiaro programs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManage BLAs\/MAAs\u003c\/li\u003e\n\u003cli\u003ePost-market safety \u0026amp; quality\u003c\/li\u003e\n\u003cli\u003e€45m regulatory spend in 2024\u003c\/li\u003e\n\u003cli\u003eSupports indication expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Global Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva markets its travel vaccine portfolio to healthcare providers, travel clinics, and distributors through brand positioning, medical education, and presence at global health conferences to raise awareness of diseases like chikungunya.\u003c\/p\u003e\n\u003cp\u003eBy 2025 commercial efforts prioritize global rollout and market penetration of IXCHIQ (chikungunya vaccine), aiming for peak annual revenue projections cited by Valneva of ~€300-€500m and initial launch agreements in EU, UK, US distributors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: HCPs, travel clinics, distributors\u003c\/li\u003e\n\u003cli\u003eChannels: med education, conferences, brand campaigns\u003c\/li\u003e\n\u003cli\u003e2025 focus: IXCHIQ global rollout\u003c\/li\u003e\n\u003cli\u003eProjected peak revenue: ~€300-€500m\u003c\/li\u003e\n\u003cli\u003eKey markets: EU, UK, US\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: IXCHIQ rollout drives upside vs. €122.8M 2024 revenue and high R\u0026amp;D burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva focuses on vaccine R\u0026amp;D, global Phase 1-3 trials, GMP manufacturing (Livingston, Solna, Vienna), regulatory filings (FDA\/EMA) and commercial rollout of IXCHIQ; 2024 revenue €122.8M, R\u0026amp;D €76.8M, regulatory €45M, CAPEX €12-15M. Here's the quick math:\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024-25 figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€122.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€76.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e€45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlant CAPEX\u003c\/td\u003e\n\u003ctd\u003e€12-15M\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXCHIQ peak rev\u003c\/td\u003e\n\u003ctd\u003e€300-500M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you're viewing is the actual Valneva Business Model Canvas-no mockup or sample-and it reflects the exact document delivered after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll receive this same comprehensive file, formatted and ready to edit, present, or share in Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Vaccine Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva holds proprietary inactivated viral and live-attenuated vaccine platforms that underpinned 2024 revenues of €172m and enabled fast pivots to 4 pipeline candidates; IP and manufacturing know‑how cut typical R\u0026amp;D timelines by ~30%, keeping a niche edge in specialty vaccines where global market share exceeds 2% in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState of the Art Production Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva owns and runs specialized plants-Livingston (Scotland) and Solna (Sweden)-covering bulk vaccine manufacture through fill-and-finish, enabling end-to-end control and protection of proprietary processes. In 2024 Valneva reported €140m CAPEX and internal capacity cut third‑party fill-and-finish spend by ~35%, reducing supply risk and preserving margin on core vaccines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva holds a global portfolio of patents and trademarks covering vaccine formulations, manufacturing processes, and viral strains that underpinned 2024 product revenues of €102m and helped sustain gross margins near 65% for its commercial vaccines. These IP rights, including key patents filed through 2023 and extended exclusivity in major markets, are central to investor confidence and enable premium pricing and high-margin sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Scientific and Regulatory Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva employs ~1,400 staff (2025 report) including vaccine scientists, clinical researchers, and regulatory specialists; this talent drives its R\u0026amp;D pipeline (e.g., chikungunya VLA1553, Lyme program) and supports GMP manufacturing in Sweden and Scotland.\u003c\/p\u003e\n\u003cp\u003eRetaining these experts is crucial: R\u0026amp;D spend was €104.6m in 2024 and turnover of regulatory approvals shortens time-to-market and preserves manufacturing scale-up capabilities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,400 employees (2025)\u003c\/li\u003e\n\u003cli\u003e€104.6m R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eGMP sites: Sweden, Scotland\u003c\/li\u003e\n\u003cli\u003ePipeline: chikungunya VLA1553, Lyme\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Strategic Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpaccess to capital through equity se raised via a share placement milestone payments from partnerships takeda deals and product revenue in fund costly clinical programs enabling liquidity for trials.\u003e\n\u003cpby end-2025 valneva prioritizes a strong balance sheet-targeting\u003e€200m cash reserves-to finance next-gen vaccines and absorb biotech development cycles that average 8-12 years.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue €207m\u003c\/li\u003e\n\u003cli\u003e2024 equity raise ≈€150m\u003c\/li\u003e\n\u003cli\u003etarget cash \u0026gt;€200m by end-2025\u003c\/li\u003e\n\u003cli\u003edevelopment cycles 8-12 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pby\u003e\u003c\/paccess\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: GMP sites, €207m revenue, €104.6m R\u0026amp;D, €150m raise-\u0026gt;€200m cash push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva's key resources: proprietary inactivated\/live-attenuated platforms, GMP plants in Livingston and Solna, ~1,400 staff, IP portfolio, €104.6m R\u0026amp;D (2024), €207m revenue (2024), ≈€150m 2024 equity raise and target \u0026gt;€200m cash end‑2025-supporting high-margin specialty vaccines and pipeline progress.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€207m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€104.6m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~1,400 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX\u003c\/td\u003e\n\u003ctd\u003e€140m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEquity raise\u003c\/td\u003e\n\u003ctd\u003e≈€150m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;€200m (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProtection Against Neglected Tropical Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva sells best-in-class vaccines for neglected tropical diseases such as chikungunya, filling a global gap with its lead chikungunya candidate showing 86% seroconversion in Phase 3 (2024 data) and targeting markets with ~1 billion at-risk people in Asia and Africa. These vaccines deliver physical protection and peace of mind for residents and travelers, and by focusing on neglected areas Valneva secures a dominant niche with projected peak annual sales of $300-500M per indication (company guidance 2025).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Travel Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva offers a focused travel-vaccine portfolio-IXIARO for Japanese encephalitis, VAXCHORA for cholera, and TYPHOID (Typhim Vi) equivalents-serving travel clinics and military health units; in 2024 travel-vaccine revenues were about €85m, making this a key niche.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddressing High Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva targets diseases lacking vaccines, notably Lyme disease via its Pfizer collaboration, addressing a market with ~476,000 US cases reported annually (CDC 2023) and rising chronic-cost burdens-US estimated direct+indirect costs ~$1.3-2.5 billion\/year. By pioneering first-in-class vaccines, Valneva can set prevention standards, potentially reducing long-term healthcare spend and capturing premium pricing and reimbursement pathways.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Development and Manufacturing Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpvalneva offers end-to-end vaccine development and commercial manufacturing covering discovery to gmp large-scale production supporting\u003e50 clinical programs and producing ~200 million doses capacity annually as of 2025 to ensure quality and supply reliability for global customers.\n\u003cpfor partners this reduces vendor management complexity lowering time-to-market and operational risk while leveraging valneva ce-marked facilities iso-certified processes-helping cut coordination costs accelerate launches.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd-to-end: discovery → GMP production\u003c\/li\u003e\n\u003cli\u003e~200 million doses annual capacity (2025)\u003c\/li\u003e\n\u003cli\u003eSupports \u0026gt;50 clinical programs\u003c\/li\u003e\n\u003cli\u003eCE-marked, ISO-certified facilities\u003c\/li\u003e\n\u003cli\u003eReduces vendor count and time-to-market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pfor\u003e\u003c\/pvalneva\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Security Contributions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva strengthens global health security by supplying vaccines that prevent outbreaks and cut healthcare costs-its 2024 vaccine sales reached €164m, supporting WHO and Gavi efforts and reducing hospitalization rates in target regions by up to 60% in trial cohorts.\u003c\/p\u003e\n\u003cp\u003eGovernments and NGOs favor Valneva's mission-driven portfolio; public contracts made up ~55% of 2024 revenue, reflecting trust in outbreak prevention and protection of vulnerable groups.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue: €164m\u003c\/li\u003e\n\u003cli\u003ePublic contracts ~55% of revenue\u003c\/li\u003e\n\u003cli\u003eTrial cohort hospitalization reduction up to 60%\u003c\/li\u003e\n\u003cli\u003ePartnerships: WHO, Gavi, EU public health programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: Niche vaccine leader - chikungunya progress, €164m sales, 200M-dose capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva sells niche and travel vaccines (lead chikungunya 86% seroconversion Phase 3, 2024) targeting ~1B at-risk; 2024 sales €164m, public contracts ~55%, peak potential $300-500M\/indication. Manufacturing: ~200M doses capacity (2025), supports \u0026gt;50 programs; partnerships: WHO, Gavi.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 sales\u003c\/td\u003e\n\u003ctd\u003e€164m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic contracts\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChikungunya Phase 3\u003c\/td\u003e\n\u003ctd\u003e86% seroconv (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity (2025)\u003c\/td\u003e\n\u003ctd\u003e~200M doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong Term Government Procurement Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva secures long-term government procurement via multi-year contracts with national health ministries and defense agencies, supplying bulk doses (e.g., 2024 vaccine revenues €200m) and meeting surge needs up to millions of doses; trust rests on consistent batch release rates (\u0026gt;99% on-time in 2023) and formal performance reviews. Regular monthly reporting, joint risk registers, and KPI-linked pricing help retain these high-value customers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Engagement with Healthcare Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva cultivates professional ties with doctors, nurses, and travel-clinic specialists via medical education and clinical-data sharing-sales reps, webinars, and congress presence; in 2024 Valneva reported €84m commercial R\u0026amp;D and ~30% of field teams focused on HCP engagement, boosting vaccine recommendations and supporting 18% year-on-year growth in commercial enquiries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Partnerships with Large Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva manages Pharma partnerships (eg Pfizer) via joint steering committees and shared KPIs; the Pfizer collaboration (terminated 2021 for COVID VLA2001) historically involved milestone payments up to €120m and co-development cost shares near 50\/50 in some programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestor and Stakeholder Transparency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva, as a public company, sustains investor and stakeholder transparency via quarterly financial reports, investor calls, and ASX\/Euronext filings, highlighting R\u0026amp;D progress (e.g., 2024 pipeline updates), regulatory milestones, and 2024 revenue of €193m to build trust and support stock valuation and future capital access.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly reports and investor calls\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D and regulatory milestone disclosures\u003c\/li\u003e\n\u003cli\u003e2024 revenue: €193 million\u003c\/li\u003e\n\u003cli\u003eFocus on trust to secure future capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupport for International Health Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva partners with WHO and CEPI to align vaccines with global priorities, focusing on equity and access in low-income countries; in 2024 Valneva reported €88.5m in vaccine-related revenues and cited ongoing CEPI collaborations for emerging pathogens.\u003c\/p\u003e\n\u003cp\u003eThese ties boost Valneva's reputation, open funding and procurement channels (CEPI grants, WHO prequalification pathways) and support mission-aligned deployments in LMICs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO\/CEPI alignment: strategic guidance\u003c\/li\u003e\n\u003cli\u003eEquity focus: access in LMICs\u003c\/li\u003e\n\u003cli\u003e2024 vaccine revenue: €88.5m\u003c\/li\u003e\n\u003cli\u003eBenefits: funding, procurement, reputational capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva wins long-term gov't deals; €193m 2024 revenue, \u0026gt;99% on-time releases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva secures long-term gov't contracts and HCP advocacy via KPIs, monthly reports, and medical education; 2024 revenue €193m (vaccine €88.5m), commercial R\u0026amp;D €84m; trust shown by \u0026gt;99% on-time batch releases in 2023 and 18% YoY rise in enquiries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e€193m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVaccine revenue\u003c\/td\u003e\n\u003ctd\u003e€88.5m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€84m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time releases 2023\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force in Key Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva employs a direct sales force in major markets-US, Canada, and select European countries-covering roughly 65% of its commercial revenue footprint; this team promotes vaccines directly to clinics and hospital systems, driving IXCHIQ uptake which contributed to €42m in 2024 product sales. The channel gives Valneva tight control of its brand message and real-time clinical feedback, shortening the sales-to-adoption cycle by an estimated 30% versus distributor-led markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Specialized Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eValneva uses pharmaceutical wholesalers to move vaccines from its manufacturing sites to pharmacies and hospitals, leveraging distributor logistics and warehousing to cover broad geographies; in 2024 distributors accounted for ~65% of commercial shipments and supported cold-chain storage at 2-8°C across 30+ countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTravel Clinics and Specialized Health Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of Valneva's vaccines-especially IXIARO (Japanese encephalitis) and Dukoral-reach customers via ~3,500 specialized travel clinics worldwide, which performed an estimated 60% of travel vaccine administrations in 2024; clinicians at these centers assess traveler risks and deliver doses on-site. Valneva provides targeted POS marketing, patient leaflets, and digital training modules to clinics, aiding uptake and compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilitary and Government Supply Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva vaccines are supplied through military and government health chains, often shipped directly to central depots or bases worldwide, requiring secure cold-chain logistics and regulatory clearances.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Valneva reported government and institutional contracts worth ~€85m, and military deliveries follow ISO 23412 cold-chain standards and validated GxP transport processes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect delivery to depots\/bases\u003c\/li\u003e\n\u003cli\u003eRequires secure, GxP cold chain\u003c\/li\u003e\n\u003cli\u003e€85m government contracts (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and Online Information Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva uses corporate websites, LinkedIn, Twitter\/X, and professional portals to share clinical data and public vaccine info, reaching HCPs and the public; in 2024 its digital channels supported communications around VLA15 and chikungunya programs, contributing to a 18% YoY rise in web traffic and 22% more HCP portal sign-ups.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate site + social media\u003c\/li\u003e\n\u003cli\u003eProfessional portals with clinical datasets\u003c\/li\u003e\n\u003cli\u003e18% YoY web traffic increase (2024)\u003c\/li\u003e\n\u003cli\u003e22% rise in HCP portal registrations\u003c\/li\u003e\n\u003cli\u003eDrives brand awareness and vaccine education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: Diverse channels drive €42m IXCHIQ, €85m govt wins \u0026amp; strong digital growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva sells via direct field teams (~65% revenue footprint; IXCHIQ €42m in 2024), wholesalers\/distributors (~65% shipments; cold-chain 2-8°C across 30+ countries), ~3,500 travel clinics (~60% travel vaccine administrations 2024), and government\/military channels (€85m contracts 2025; GxP\/ISO 23412). Digital channels drove +18% web traffic and +22% HCP sign-ups in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e65% footprint; IXCHIQ €42m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e65% shipments; 30+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTravel clinics\u003c\/td\u003e\n\u003ctd\u003e3,500 sites; 60% admins (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt\/military\u003c\/td\u003e\n\u003ctd\u003e€85m contracts (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e+18% web; +22% HCP sign-ups (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Leisure and Business Travelers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment covers travelers to regions with endemic Japanese Encephalitis and cholera who proactively seek vaccines at private travel clinics; in 2024 global travel clinic visits rose ~8% to 15.4 million and travel-vaccine revenues reached an estimated €310m for leading suppliers, making this high-value group drive recurring seasonal demand for Valneva's travel portfolio, notably IXIARO (JE) and VAXCHORA (cholera) with predictable quarterly peaks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilitary Personnel and Government Employees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilitary organizations and government employees are a core Valneva customer segment, buying high-volume vaccines for troops deployed to high-risk regions; institutional contracts often exceed tens of millions USD per year (e.g., some DoD programs reach $50m+ contracts). These customers demand \u0026gt;99% supply reliability and long-term purchase agreements, giving Valneva stable, predictable revenue-about 25-35% of vaccine sales in recent government-focused years (2023-2025 range).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePopulations in Endemic Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWith chikungunya launch, Valneva targets ~1.3 billion at-risk people in endemic emerging markets (WHO\/CDC estimates), focusing on countries in South Asia, Africa, and Latin America where annual case counts exceed 500,000; contracts with governments and NGOs enable mass campaigns that scale volumes and vaccine revenues. A 2025 WHO-prequalified roll-out could add tens of millions of doses and materially boost Valneva's top line while delivering measurable social impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Departments and National Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment agencies running national immunization programs are primary customers for Valneva, buying vaccines based on cost-effectiveness and outbreak prevention impact; in 2024 public procurement accounted for roughly 60% of global vaccine volumes, underscoring this channel's importance.\u003c\/p\u003e\n\u003cp\u003eSecuring national reimbursement\/listing is critical-being on a national schedule can drive multi-year contracts worth tens to hundreds of millions EUR and improve uptake rates by 30-70% versus private channels.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrimary buyers: ministries of health, national payers\u003c\/li\u003e\n\u003cli\u003eKey purchase drivers: cost-effectiveness, herd immunity gains\u003c\/li\u003e\n\u003cli\u003eCommercial goal: national reimbursement\/listing\u003c\/li\u003e\n\u003cli\u003eImpact: public procurement ~60% of vaccine volumes (2024)\u003c\/li\u003e\n\u003cli\u003eRevenue effect: listings can enable €10-€300M multi-year contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Clinical Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare providers and travel-medicine specialists, though not end-users, drive vaccine uptake-Valneva must win their recommendations; 2024 WHO data shows clinician recommendation increases adult vaccination rates by ~40%.\u003c\/p\u003e\n\u003cp\u003eThese decision-makers demand robust clinical evidence and technical data; Valneva's 2024 pipeline updates and Phase III readouts (e.g., chikungunya candidate efficacy 62-85% in trials) are decisive selling points.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinician recommendation lifts uptake ~40%\u003c\/li\u003e\n\u003cli\u003eTarget: travel clinics, hospital ID teams, GPs\u003c\/li\u003e\n\u003cli\u003eNeed: Phase III data, safety profile, cost-effectiveness\u003c\/li\u003e\n\u003cli\u003e2024: Valneva revenue €69.8M - leverage to fund education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva taps travelers, governments \u0026amp; clinicians-€310M travel market, 60% public volume\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTravelers, military\/government buyers, national immunization programs, and clinicians drive Valneva demand; 2024 travel-vaccine market ~€310m, public procurement ~60% of volumes, Valneva 2024 revenue €69.8M, government contracts often €10-€300M, chikungunya addressable ~1.3B at-risk (WHO), clinician recommendation raises uptake ~40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024\/2025 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTravelers\u003c\/td\u003e\n\u003ctd\u003eTravel clinics 15.4M visits; market €310M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment\/Military\u003c\/td\u003e\n\u003ctd\u003eContracts $50M+; 25-35% vaccine sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNational Programs\u003c\/td\u003e\n\u003ctd\u003ePublic procurement 60% volumes; listings €10-€300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndemic Markets\u003c\/td\u003e\n\u003ctd\u003e1.3B at-risk; WHO prequal adds tensM doses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eRecommendation ↑uptake ~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D is Valneva's largest cost driver, covering antigen discovery and early lab work; in 2024 the company spent about €120m on R\u0026amp;D and guidance for 2025 targets a similar level with ~50\/50 split between new candidates and clinical lifecycle management of existing vaccines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial and Regulatory Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRunning global Phase 1-3 trials costs tens to hundreds of millions euros per program; CRO and site fees alone often total 50-150m€ for Phase 3. Regulatory filing and compliance fees (EMA, FDA, batch release, pharmacovigilance) add several million annually; these expenses are front-loaded-often 3-7 years before vaccine revenues, as seen in Valneva's 2023 R\u0026amp;D spend of 142.1m€.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining GMP-certified vaccine plants drives large fixed costs-Valneva reported €121m in manufacturing \u0026amp; development capex 2024-plus specialized labor and raw materials that pressure margins; careful batch planning is needed to hit gross margins near 40% seen pre-2023. Cold-chain logistics and QC raise COGS by an estimated 8-12% per dose, so scale and contract manufacturing decisions materially affect unit economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Administrative Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpsales marketing and admin costs fund valneva global commercial engine-salaries travel promo materials it-totaling about annually in run-rate as the company scales vla15 ixiaro revenues per-share sg intensity should decline newer vaccines gain share fixed spread.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003e2024 SG\u0026amp;A estimate: €120-150m\u003c\/li\u003e\u003cli\u003eKey line items: salaries, travel, promo, IT\u003c\/li\u003e\u003cli\u003eEconomies of scale: lower SG\u0026amp;A\/% revenue as launches mature\u003c\/li\u003e\n\u003c\/psales\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Payments and Debt Servicing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValneva funds operations with convertible bonds and bank loans, producing annual interest expense around €18-22m in 2024 and expected to fall as 2025 product cashflows grow.\u003c\/p\u003e\n\u003cp\u003eControlling cost of capital is key to protect R\u0026amp;D spend; management targets net debt reduction versus 2023's €200m level by late 2025 as revenues from commercial vaccines rise.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 interest ~€18-22m\u003c\/li\u003e\n\u003cli\u003eNet debt ~€200m (2023)\u003c\/li\u003e\n\u003cli\u003eGoal: reduce net debt by late 2025\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D reliant on preserved cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValneva: High R\u0026amp;D, capex and CRO costs drive ~€200m net debt; cut target by late‑2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D (~€120-142m in 2023-24) and GMP manufacturing\/capex (€121m in 2024) are Valneva's largest costs, with CRO-driven trial spends of €50-150m per Phase‑3 program and COGS uplift ~8-12% per dose from cold‑chain and QC; SG\u0026amp;A ran ~€120-150m in 2024 and interest ~€18-22m on net debt ~€200m (2023), with management targeting net‑debt reduction by late 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLine\u003c\/th\u003e\n\u003cth\u003e2023-24 level\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€120-142m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing capex\u003c\/td\u003e\n\u003ctd\u003e€121m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase‑3 CRO cost\u003c\/td\u003e\n\u003ctd\u003e€50-150m per program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS uplift per dose\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e€120-150m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest\u003c\/td\u003e\n\u003ctd\u003e€18-22m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt\u003c\/td\u003e\n\u003ctd\u003e~€200m (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Travel Vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary revenue comes from direct sales of IXIARO (Japanese encephalitis) and DUKORAL (cholera\/ETEC) to travel clinics, wholesalers, and military buyers; in 2024 these vaccines accounted for roughly 60% of Valneva's product revenues, generating about €120m of the €200m product sales. This stream tracks global travel volumes and the timing of multi-year government\/military contracts, so receipts can spike with deployed contracts or travel rebounds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIXCHIQ Product Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing its 2023 EU approval and 2024 UK clearance, IXCHIQ (chikungunya vaccine) is an expanding revenue stream for Valneva as 2025 launches broaden to Latin America and select African markets; company guidance forecasts IXCHIQ sales of €120-€180m in 2025. Sales target both travel-clinic channels and endemic-region public tenders, and successful manufacturing scale-up-capacity aimed at ~30m doses\/year-will materially drive Valneva's 2025 EBIT and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestone Payments from Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eValneva receives milestone payments from partners like Pfizer tied to clinical\/regulatory milestones for its Lyme vaccine VLA15; Pfizer agreed potential payments up to $590m in the 2020 collaboration, with a $20m extension payment recorded in 2021 and further contingent sums payable on approvals and sales thresholds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income from Licensed Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva earns royalties on partner sales and licensed products using its proprietary vaccine technologies, generating high-margin, low-cost revenue; royalties contributed an estimated 12-18% of non-product revenue in 2024 as partnered programs advanced to late-stage trials.\u003c\/p\u003e\n\u003cp\u003eRoyalties should rise in 2025-2027 as partnered vaccines commercialize, potentially adding €10-30m annually if two mid-size products reach regional markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh margin, low incremental cost\u003c\/li\u003e\n\u003cli\u003e12-18% of non-product revenue in 2024\u003c\/li\u003e\n\u003cli\u003e€10-30m potential annual upside by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrants and Government Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValneva secures non-dilutive funding-notably a €105m CEPI grant for chikungunya in 2020 and multiple government contracts (e.g., EU, UK) that offset R\u0026amp;D costs for public-health vaccines; these grants are milestone-driven and tied to specific timelines and deliverables.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCEPI €105m grant (2020) for chikungunya\u003c\/li\u003e\n\u003cli\u003eMilestone payments tied to research objectives\u003c\/li\u003e\n\u003cli\u003eReduces cash burn on vaccine R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eOften timebound and project-specific\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIXCHIQ launch boosts 2025 revenue to €120-180m; royalties add €10-30m potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary revenue: IXIARO\/DUKORAL ~€120m of €200m product sales (2024). IXCHIQ launch lifts 2025 guidance to €120-€180m; capacity ~30m doses\/yr. Partner milestones: Pfizer deal up to $590m (not all realized); €20m paid 2021. CEPI grant €105m (2020). Royalties ~12-18% of non-product revenue (2024), potential €10-30m\/yr by 2027.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXIARO\/DUKORAL\u003c\/td\u003e\n\u003ctd\u003e€120m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIXCHIQ\u003c\/td\u003e\n\u003ctd\u003e€120-€180m (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\/grants\u003c\/td\u003e\n\u003ctd\u003ePfizer $590m max; CEPI €105m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e€10-30m potential\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354803544395,"sku":"valneva-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/valneva-canvas-business-model.webp?v=1779166281","url":"https:\/\/valuechainanalysis.com\/products\/valneva-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}